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(US) The present invention discloses a method of monitoring haptotaxis comprising: providing a device for monitoring haptotaxis having a housing defining a chamber. The cham ber includes: a first well region including at least one first well, the first well region configured to receive a test agent therein and further including biomolecules immobilized therein; a Second well region including at least one Second well, the Second well region configured to receive a Sample comprising cells therein and further being horizontally offset with respect to the first well region in a test orientation of the device; and a channel region with biomolecules immobilized therein and including at least one channel connecting the first well region and the Second well region with one another. The method also includes forming a Surface concentration gradient along a longitudinal axis of the chamber by decreasing the concentration of biomolecules from the at least one first well to the at least one Second well, placing a first Sample comprising cells in the at least one Second well; and monitoring haptotaxis of the cells. The present invention relates generally to a method of monitoring haptotaxis.
BACKGROUND
Test devices, Such as those used in chemotaxis, haptotaxis and chemoinvasion are well known. Such devices are dis closed for example in U.S. Pat. Nos. 6, 329, 164, 6, 238, 874, and 5, 302, 515. Three processes involved in cell migration are chemotaxis, haptotaxis, and chemoinvasion. Chemotaxis is defined as the movement of cells induced by a concentration gradient of a Soluble chemotactic Stimulus. Haptotaxis is defined as the movement of cells in response to a concen tration gradient of a Substrate-bound Stimulus. Chemoinva Sion is defined as the movement of cells into and/or through a barrier or gel matrix. The Study of chemotaxis/haptotaxis and chemoinvasion and the effects of external Stimuli on Such behavior are prevalent throughout contemporary bio logical research. Generally, this research involves exposing a cell to external Stimuli and Studying the cell's reaction. By placing a living cell into various environments and exposing it to different external stimuli, both the internal workings of the cell and the effects of the external stimuli on the cell can be measured, recorded, and better understood.
A cell's migration in response to a chemical Stimulus is a particularly important consideration for understanding vari ous disease processes and accordingly developing and evaluating therapeutic candidates for these diseases. By documenting the cell migration of a cell or a group of cells in response to a chemical Stimulus, Such as a therapeutic agent, the effectiveness of the chemical Stimulus can be better understood. Typically, Studies of disease processes in various medical fields, Such as oncology, immunology, angiogenesis, wound healing, and neurobiology involve analyzing the chemotactic and invasive properties of living cells. For example, in the field of oncology, cell migration is an important consideration in understanding the process of metastasis. During metastasis, cancer cells of a typical Solid tumor must loosen their adhesion to neighboring cells, escape from the tissue of origin, invade other tissues by degrading the tissues extracellular matrix until reaching a blood or lymphatic vessel, croSS the basal lamina and endothelial lining of the vessel to enter circulation, exit from circulation elsewhere in the body, and Survive and prolifer ate in the new environment in which they ultimately reside. Therefore, Studying the cancer cells migration may aid in understanding the process of metastasis and developing therapeutic agents that potentially inhibit this process. In the   5   15   25   35   40   45   50   55   60   65   2 inflammatory disease field, cell migration is also an impor tant consideration in understanding the inflammatory response. During the inflammation response, leukocytes migrate to the damaged tissue area and assist in fighting the infection or healing the wound. The leukocytes migrate through the capillary adhering to the endothelial cells lining the capillary. The leukocytes then Squeeze between the endothelial cells and use digestive enzymes to crawl acroSS the basal lamina. Therefore, Studying the leukocytes migrat ing acroSS the endothelial cells and invading the basal lamina may aid in understanding the inflammation process and developing therapeutic agents that inhibit this process in inflammatory diseaseS Such as adult respiratory distress sydrome (ARDS), rheumotoid arthritis, and inflammatory skin diseases. Cell migration is also an important consider ation in the field of angiogenesis. When a capillary Sprouts from an existing Small vessel, an endothelial cell initially extends from the wall of the existing Small vessel generating a new capillary branch and pseudopodia guide the growth of the capillary Sprout into the Surrounding connective tissue. New growth of these capillaries enables cancerous growths to enlarge and spread and contributes, for example, to the blindness that can accompany diabetes. Conversely, lack of capillary production can contribute to tissue death in cardiac muscle after, for example, a heart attack. Therefore Studying the migration of endothelial cells as new capillaries form from existing capillaries may aid in understanding angio genesis and optimizing drugs that block vessel growth or improve vessel function. In addition, Studying cell migration can also provide insight into the processes of tissue regeneration, organ transplantation, autoimmune diseases, and many other degenerative diseases and conditions.
Cell migration assays are often used in conducting these types of research. Commercially available devices for cre ating Such assays are Sometimes based on or employ a transwell System (a vessel partitioned by a thin porous membrane to form an upper compartment and a lower compartment). To study cell chemotaxis, cells are placed in the upper compartment and a migratory Stimulus is placed in the lower compartment. After a Sufficient incubation period, the cells are fixed, Stained, and counted to study the effects of the Stimulus on cell chemotaxis across the membrane.
To study chemoinvasion, a uniform layer of a MATRI GELTM matrix is placed over the membrane to occlude the pores of the membrane. Cells are seeded onto the MATRI GELTM matrix in the upper compartment and a chemoat tractant is placed in the lower compartment. Invasive cells attach to and invade the matrix passing through the porous membrane. Non-invasive cells do not migrate through the occluded pores. After a Sufficient incubation period, the cells may be fixed, Stained, and counted to Study the effects of the Stimulus on cell invasion acroSS the membrane.
The use of transwells has Several shortcomings. ASSayS employing transWells require a labor-intensive protocol that is not readily adaptable to high-throughput Screening and processing. Because of the configuration of a transwell System, it is difficult to integrate with existing robotic liquid handling Systems and automatic image acquisition Systems. Therefore, much of the Screening and processing, Such as counting cells, is done manually which is a time-consuming, tedious, and expensive proceSS. Cell counting is also Sub jective and often involves Statistical approximations. Specifically, due to the time and expense associated with examining an entire filter, only randomly Selected represen tative areas may be counted. Moreover, even when these areas are counted, a technician must exercise his or her judgment when accounting for a cell that has only partially migrated through the filter. TranSwell-based assays have intrinsic limitations imposed by the thin membranes utilized in transwell systems. The membrane is only 50-30 microns (um) thick, and a chemical concentration gradient that forms across the membrane is transient and lasts for a short period. If a cell chemotaxis assay requires the chemotactic gradient to be generated over a long distance (>100-200 um) and to be stable over at least two hours, currently available transwell assays cannot be Satisfactorily performed.
Notwithstanding the above, perhaps the most significant disadvantage of transWells is the lack of real-time observa tion of chemotaxis and chemoinvasion. In particular, the changes in cell morphology during chemotaxis cannot be observed in real-time with the use of transwells. In transwells, when the cells are fixed to a slide, as required for observation, they are killed. Consequently, once a cell is observed it can no longer be reintroduced into the assay or Studied at Subsequent periods of exposure to a test agent. Therefore, in order to Study the progreSS of a cell and the changes in a cell's morphology in response to a test agent, it is necessary to run concurrent Samples that may be slated for observation at various time periods before and after the introduction of the test agent. In light of the multiple Samples required for each test, in addition to the positive and negative controls required to obtain reliable data, a Single chemotaxis assay can require dozens of filters, each of which needs to be individually examined and counted-an onerous and time-consuming task.
More recently, devices for measuring chemotaxis and chemoinvasion have become available which employ a configuration in which two wells are horizontally offset with respect to one another. This configuration of a device was introduced by Sally Zigmond in 1977 and, hereafter referred to as the "Zigmond device," consists of a 25 millimeters (mm)x75 mm glass slide with two grooves 4 mm wide and 1 mm deep, Separated by a 1 mm bridge. One of the grooves is filled with an attractant and the other groove is filled with a control Solution, thus forming a concentration gradient acroSS the bridge. Cells are then added to the other groove. Two holes are provided at each end of the Slide to accept pin clamps. The clamps hold a cover glass in place during incubation and observation of the cells. Because of the size and configuration of the Zigmond chamber, it does not allow integration with existing robotic liquid handling Systems and automatic image acquisition Systems. Further, as with transwell-based Systems, the changes in cell morphology during chemotaxis cannot be observed in real-time with the use of the Zigmond chamber as the cells are fixed to a slide for observation. In addition, the pin clamps must be assembled with an allen wrench and thus the device requires extra handling, positioning, and alignment before perform ing the assay. Such handling and positioning of the cover glass on the glass Slide, as well as the rigidity of the cover glass, can potentially damage or interfere any Surface treat ment on the bridge.
A chemotaxis device attempting to Solve the problem of lack of real-time observation is the "Dunn chamber." The Dunn chamber consists of a specially constructed microSlide with a central circular Sink and a concentric annular moat. In an assay using a Dunn chamber, cells migrate on a coverslip, which is placed inverted on the Dunn chamber, towards a chemotactic Stimulus. The cells are monitored over-night using a phase-contrast microscope fitted with a video camera connected to a computer with an image-grabber board. In addition to the problems of rigidity of the coverslip and the lack of integration into existing robotic liquid handling Systems, a major problem with the Dunn chamber assay is The prior art has failed to provide a test device, Such as a device for monitoring chemotaxis, haptotaxis, and/or chemoinvasion, which device is easily assembled and dis Sembled. In addition, the prior art has failed to provide a test device for monitoring chemotaxis and/or chemoinvasion, which is not limited to measuring the effects on cell migra tion of chemoattractants, chemorepellants and chemoStimu lants.
SUMMARY OF THE INVENTION
The present invention provide a method of monitoring haptotaxis. The method includes providing a device for monitoring haptotaxis having a housing defining a chamber. The chamber includes a first well region including at least one first well, the first well region configured to receive a test agent therein and further including biomolecules immobi lized therein; a Second well region including at least one Second well, the Second well region configured to receive a Sample comprising cells therein and further being horizon tally offset with respect to the first well region in a test orientation of the device, and a channel region with biomol ecules immobilized therein and including at least one chan nel connecting the first well region and the Second well region with one another. The method further includes form ing a Surface concentration gradient along a longitudinal axis of the chamber by decreasing the concentration of biomolecules from the at least one first well to the at least one Second well. The method additionally includes placing a first Sample comprising cells in the at least one Second well. The method also includes monitoring haptotaxis of the cells.
BRIEF DESCRIPTION OF THE DRAWINGS
The various features of the invention will best be appre ciated by Simultaneous reference to the description that follows and the accompanying drawings, in which:
FIG in FIG. 1C , each well is defined by a through-hole in top member 11, corresponding to well 13 and well 14 respectively, and by an upper surface U of Support member 16. In particular, the sides of each well 13 and 14 are defined by the walls of the through holes in the top member 11, and the bottoms of well 13 and 14 are defined by the upper Surface U of Support member 16. It is noted that in the context of the present invention, "top,' "bottom," "upper" and "side" are defined relative to the test orientation of the device. As seen collectively in FIGS. 1A and 1C, a length L of channel region 15a is defined in a direction of the longitudinal axis of channel region 15a, a depth D of channel region 15a is defined in a direction normal to upper surface U of support member 16; a width W is defined in a direction normal to the length L and depth D of channel region 15a. According to one embodiment of the present invention, the chamber's first well 13 is adapted to receive a test agent, a In one embodiment of the present invention, when a Soluble test Substance is used as the test agent, channel region 15a preferably contains a gel matrix. The gel matrix allows the formation of a Solution concentration gradient from first well region 13a towards second well region 14a as the Solute diffuses from an area of higher concentration (well region 13a) through a semi-permeable matrix (the gel matrix) to an area of lower concentration (well region 14a).
If the Soluble test Substance comprises a chemoattractant, in order for the cells to migrate through the matrix in the direction of the Solution concentration gradient towards well region 13a, the cells must degrade this matrix by releasing enzymes Such as matrix metalloproteases. This cell chemo taxis and invasion may be Subsequently observed, measured, and recorded.
In one embodiment of the present invention, utilizing immobilized biomolecules as the test agent, the biomol ecules are preferably immobilized or bound on the portion of Support member 16 underlying channel region 15a and underlying through hole for well region 13a. The concen tration of biomolecules decreases along the longitudinal axis of the device from well region 13a towards well region 14a forming a Surface concentration gradient of immobilized biomolecules and the biological Sample of cells potentially responds to this Surface gradient. This cell haptotaxis may be Subsequently observed, measured, and recorded.
With respect to particular specifications of device 10, top member 11 is made of a material that is adapted to effect conformal contact, preferably reversible conformal contact, with support member 16. According to embodiments of the present invention, the flexibility of Such a material, among other things, allows the top member to form-fittingly adhere to the upper Surface U of Support member 16 in Such a way as to form a substantially fluid-tight seal therewith. The conformal contact should preferably be strong enough to prevent Slippage of the top member on the Support member surface. Where the conformal contact is reversible, the top member may be made of a material having the Structural integrity to allow the top member to be removed by a simple peeling process. This would allow top member 11 to be removed and cells at certain positions collected. Preferably, the peeling process does not disturb any Surface treatment or cell positions of Support member 16. Physical Striations, pockets, SAMs, gels, peptides, antibodies, or carbohydrates can be placed on Support member 16 and the top member 11 Subsequently can be placed over Support member 16 without any damage to these structures. Additionally, the Substan tially fluid-tight seal effected between top member 11 and support member 16 by virtue of the conformal contact of top member 11 with Support member 16 prevents fluid from leaking from one chamber to an adjacent chamber, and also prevents contaminants from entering the Wells. The Seal preferably occurs essentially instantaneously without the necessity to maintain external pressure. The conformal con tact obviates the need to use a Sealing agent to Seal top chamber 12 by a Sealing agent. Preferably, the top member 11 is made of a material that does not degrade and is not easily damaged by Virtue of being used in multiple tests, and that affords considerable variability in the top member's configuration during manufacture of the same. More preferably, the material may be Selected for allowing the top member to be made using photolithography. In a preferred embodiment, the material comprises an elastomer Such as Silicone, natural or Synthetic rubber, or polyurethane. In a more preferred embodiment, the material is polydimethyl siloxane ("PDMS").
According to a preferred embodiment of a method of the present invention, Standard photolithographic procedures can be used to produce a Silicon master that is the negative image of any desired configuration of top member 11. For example, the dimensions of chambers 12, Such as the Size of well regions 13a and 14a, or the length of channel region 15a, can be altered to fit any advantageous Specification. Once a Suitable design for the master is chosen and the master is fabricated according to Such a design, the material is either spin cast, injected, or poured over the master and cured. Once the mold is created, this process may be repeated as often as necessary. This process not only pro vides great flexibility in the top member's design, it also allows the top members to be massively replicated. The present invention also contemplates different methods of fabricating device 10 including, for example, e-beam lithography, laser-assisted etching, and transfer printing.
Device 10 preferably fits in the footprint of an industry Standard microtiter plate. AS Such, device 10 preferably has the same outer dimensions and overall size of an industry Standard microtiter plate. Additionally, when chamber 12 comprises a plurality of chambers, either the chambers 12 themselves, or the wells of each chamber 12, may have the Same pitch of an industry Standard microtiter plate. The term "pitch' used herein refers to the distance between respective Vertical centerlines between adjacent chambers or adjacent wells in the test orientation of the device. The embodiment of device 10, shown in FIG. 1B, comprises 48 chambers designed in the format of a standard 96-well plate, with each well fitting in the Space of each macrowell of the plate. The Size and number of the plurality of chambers 12 can corre spond to the footprint of standard 24-, 96-, 384-, 768-and 1536-well microtiter plates. For example, for a 96 well microtiter plate, device 10 may comprise 48 chambers 12 and therefore 48 experiments can be conducted, and for a 384 well microtiter plate, the device may comprise 192 chambers 12, and therefore 192 experiments can be con ducted. The present invention also contemplates any other number of chambers and/or wells disposed in any Suitable configuration. For example, if pitch or footprint Standards change or new applications demand new dimensions, then device 10 may easily be changed to meet these new dimen Sions. By conforming to the exact dimension and Specifica tion of standard microtiter plates, embodiments of device 10 would advantageously fit into existing infrastructure of fluid handling, Storage, registration, and detection. Embodiments of device 10, therefore, may be conducive to high through put Screening as they may allow robotic fluid handling and automated detection and data analysis. Top member 11 may additionally take on Several different variations and embodi ments. Depending on the test parameters, Such as, for example, where chemotaxis, haptotaxis and/or chemoinva Sion are to be monitored, the cell type, cell number, or distance over which chemotaxis or haptotaxis is required, chamber 12 of top member 11 may have various embodi ments of which a few exemplary embodiments are discussed herein. With respect to a discrete chamber 12, the shape, dimensions, location, Surface treatment, and numbers of channels in channel region 15a and the shape and number of wells 13 and 14 may vary.
Regarding the shape of channel region 15a, each channel 15 in the channel region 15a is not limited to a particular croSS-Sectional shape, as taken in a plane perpendicular to its longitudinal axis. For example, the croSS Section of any given channel 15 can be hexagonal, circular, Semicircular, ellipsoidal, rectangular, Square, or any other polygonal or curved shape.
Regarding the dimensions of a channel 15, the length L of a given channel 15 can vary based on various test param eters. For instance, the length L of a given channel 15 may vary in relation to the distance over which chemotaxis or haptotaxis is required to occur. For example, the length L of a given channel 15 can range from about 3 um to about 18 mm in order to allow cells Sufficient distance to travel and therefore Sufficient opportunity to observe cell chemotaxis/ haptotaxis and chemoinvasion. The width W and depth D of a given channel 15 may also vary as a function of various test parameters. For examples, the width W and depth D of a given channel 15 may vary, in a chemotaxis, haptotaxis and/or chemoinvasion device, depending on the size of the cell being Studied and whether a gel matrix is added to the given channel 15. Generally, where the test device is a chemotaxis, haptotaxis and/or chemoinvasion device, a given channel 15's width W and depth D may be approxi mately in the range of the diameter of the cell being assayed.
To discount random cellular movement, at least one of the depth D or width W of a given channel 15 should preferably be smaller than the diameter of the cell when no gel matrix is placed in the given channel 15 So that when the cells are activated, they can "Squeeze' themselves through the given channel toward the test agent. If a given channel 15 contains a gel matrix, then, the depth D and width W of the given channel 15 may be greater than the diameter of the cell being assayed. The number of channels in channel region 15a between well regions 13a and 14a can also vary. Channel region 15a may include a plurality of channels, as shown by way of example in FIGS. 3A-3C. As seen in FIG. 3A , in a preferred configuration, the length L of each channel 15i-n between well 13 and well 14 is identical. In another embodiment as seen in FIG. 3B , the length L of each channel 15i-n of channel region 15a increases in the direction of well 14, starting from channel 15i in the side portion 12a of chamber 12 to channel 15n in the side portion 12b of chamber 12. In one embodiment, as seen in FIG. 3B , the length L of each Successive channel in the plurality of channels 15 of cham ber 12 increases in a direction of a width W of the channels with respect to a preceding one of the plurality of channels Such that respective channel inlets at one of the first well region and the Second well region, Such as well region 13a as shown, are aligned along the direction of the width W of the channels. Although, in this configuration, the cells trav eling in any particular channel will exit the channels and enter well 14 at points longitudinally offset with respect to one another, the Section of channel region 15a closest to well region 13a is positioned So that cells ultimately entering the different channels will be aligned in a direction of the width W of the channels so that there is no longitudinal offset between them. Therefore, in comparing two adjacent channels, a first group of cells entering channel 15i has an entry position that is not longitudinally offset with respect to a Second different group of cells entering channel 15i, but the first group of cells exiting channel 15i has an exit point longitudinally offset from the second group of cells exiting channel 15i. In a different embodiment of the present 4B. Non-limiting examples of endothelial cells include human umbilical vein endothelial cells or high endothelial Venule cells. In another embodiment, a given channel 15 is filled with a gel matrix Such as gelatin, agarose, collagen, fibrin, any natural or Synthetic extracellular proteinous matrix or basal membrane mimic including, but not limited to MATRIGELTM (Becton Dickenson Labware), or ECM GEL, (Sigma, St. Louis, Mo.), or other hydrogels containing certain factorS Such as cytokines, growth factors, antibodies, ligands for cell Surface receptors, or chemokines. Preferably, the gel has a Substantially high water content and is porous enough to allow cell chemotaxis and invasion. AS mentioned above, when the test agent comprising a Soluble test Sub stance is placed in well 13, the gel facilitates formation of a Solution concentration gradient along the longitudinal axis of chamber 12. Additionally, adding a gel matrix to a given channel 15 Simulates the natural environment in the body, as enzyme degradation through extracellular matrix is a crucial
Step in the invasive process.
According to the present invention, the individual wells of each well region 13a or 14a may have any shape and size. For example, the top plan contour of a given well may be circular, as shown in FIGS. 1A-2C, or trapezoidal as shown in FIGS. 5 and 6. Alternatively, the top plan contour of a given chamber may be generally in the shape of a "figure 8" as shown in FIG. 7 . Preferably when using a soluble test Substance as the test agent, the shape of well 13 is Such that soluble test Substance is readily able to access the channel 15 and thereby form the necessary Solution concentration gra dient along the length L of channel 15. Preferably, the shape of well 14 is such that cells are not deferred, detained, or hindered from migrating out of the first well 14, for example, by accumulating in a corner, Side or other dead Space of well 14. Although possible accumulation of cells in a dead Space of well 14 is not restricted to any particular cell number, there exists a greater likelihood of cells accumulating in a corner of well 14 if a large number of cells are used. Therefore to maximize accessibility to the concentration gradient and to minimize the "wasting of cells when a large cell Sample is utilized, it is important that the Shape of well 14 be Such that a Sufficiently high percentage of cells, particularly the cells in the area of well 14 furthest from channel 15, are capable of migrating out of well 14. In a different embodiment that also addresses the problem of the wasting of cells, well 14 may be shaped Such that all cells have a higher probability of accessing the concentration gradient. For example as Seen in FIG. 8 , the length L of well 14 in a top plan view thereof is minimized to decrease the Surface area of the well. AS Such, the cells are closer to the concentration gradient formed in channel 15. In a preferred embodiment, the L of well 14 in a top plan view thereof is about 1 mm to about 2 mm.
In addition to variations of components of a discrete chamber 12, the present invention also contemplates varia tions in the overall chamber 12 as well as variations from chamber to chamber. With respect to the overall chamber 12, in one embodiment, the chambers 12 are sized So that a complete chamber 12 fits into the area normally required for a single well of a 96-well plate. In this configuration, 96 different assays could be performed in a 96-well plate. In another embodiment, the 1:1 ratio of a first well to second well, as present in the aforementioned embodiments, is altered by modifying chamber 12. For example as Seen in  FIG. 9 , device 10 includes a chamber 12 having a first well region 13a having a plurality of first wells 102,103,104 and 105 connected to one another, a second well region 14a having a plurality of wells 106, 107, 108 and 109, and a channel region 15a having a plurality of channels 15 con necting respective ones of the first Wells to respective ones of the second wells. As seen in a side view of support member 16 in FIG. 12 , the upper surface U of Support member 16, which underlies top member 11, may be sloped at predetermined regions thereof with respect to a horizontal plane at less than a 90 angle. In the shown embodiment, the predetermined regions correspond to bottom Surfaces of respective wells, Surface 16a corresponding to a bottom Surface of a well 13, and surface 16b corresponding to a bottom surface of well 14. Surface 16c, in turn, corresponds to a bottom Surface of channel 15. In this embodiment, the given configuration 13 facilitates Suspended cells flowing in the direction of the downward slope of top surface 16b of support member 16 to become more readily exposed to the concentration gradient. If a soluble test Substance is used as the test agent in well 13 of device 10, then top surface 16a of support member 16 may also be downwardly sloped with respect to a horizontal plane at less than a 90° angle to facilitate exposure of the test Substance to channel 15 in order to facilitate formation of the Solution concentration gradient.
Support member 16 may also have a treatment on or embedded into its Surface. This treatment may serve numer ous functions, including, for example, facilitating the placement, adhesion or movement of cells being Studied, and Simulating in Vivo conditions. Numerous Surface con figurations and chemicals may be used alone or in conjunc tion for this treatment. For example, in one embodiment Support member 16 includes a patterned Self-assembled monolayer (SAM) on a gold surface or other suitable material. SAMs are monolayers typically formed of mol ecules each having a functional group that Selectively attaches to a particular Surface, the remainder of each molecule interacting with neighboring molecules in the monolayer to form a relatively ordered array. By using SAMs, various controls of biological interactions may be employed. For example, SAMs may be arrayed or modified with various "head groups" to produce "islands" of biospe cific Surfaces Surrounded by areas of bio-inert head groups. Further, SAMs may be modified to have "switchable Sur faces" that may be designed to capture a cell and then be Subsequently modified to release the captured cell. Moreover, it may also be desirable to utilize a bioinert Support member material to resist non-specific adsorption of cells, proteins, or any other biological material. Consequently, the use of SAMs on Support member 16 may be advantageous.
The present invention also contemplates, as Seen in FIG. 13, the use of any System known in the art to detect and analyze cell chemotaxis, haptotaxis, and chemoinvasion. In particular, the present invention contemplates the use of any System known in the art to visualize changes in cell mor phology as cells move acroSS channel 15, to measure the distance cells travel in channel 15, and to quantify the number of cells that travel to particular points in channel 15. AS Such the present invention contemplates both "real-time" and "endpoint' analysis of chemotaxis, haptotaxis, and In another embodiment, the equalization block 140 may re-Scale Sample values based on a color or wavelength. Conventional cellular analysis techniqueS often cause cells to appear in predetermined colors or with predetermined wavelengths, which permits them to be distinguished from other materials captured by the imager. For example, in 15 fluorescent applications, cells emit light at predetermined wavelengths. In nuclear Staining applications, cell nuclei are dyed with a material that causes them to appear in the image data with predetermined colors. The equalization block 140 may re-scale Sample values having components that coin cide with these expected colors or wavelengths. In So doing, the equalization block 140 effectively filters out other colors or wavelengths, a consequence that may be advantageous in later image processing.
Image rotation is another image artifact that may occur from imperfect imaging apparatus. Although the channels 15 are likely to be generally aligned with columns and rows of pixels in the image data, further analysis may be facilitated if the alignment is improved. Accordingly, in an embodiment, the image preprocessing Stage 110 may include an image alignment block 150 that rotates the captured image data to counteract this artifact. Once the rotation artifact has been removed from the captured image data, then image from individual channels 15 are likely to coincide with a regular row or column array of pixel data. Having identified a column of image data to be considered, the column 310 may be split into two boundary boxes 320,330 (block 1020). By summing the intensity of the image data in each of the two boundary boxes and comparing Summed values to each other, an orientation of the rotation artifact may be determined (blocks 1030, 1040).
In the example of FIG. 17 , the rotation artifact causes more of second well 14 to fall within the area of boundary box320 than of boundary box 330 (a clockwise artifact). The image data may be rotated counterclockwise until the Summed values of each boundary box 320, 330 become balanced.
Thus, if the image intensity of the first bounding box is greater than that of the second bounding box 330, the image data may be rotated in a first direction (block 1050). If the image intensity of the Second bounding box 330 is greater than that if the first bounding box 320, the image data may be rotated in a second direction (block 1060). And when the image intensities are balanced, the method 1000 may con clude; the rotation artifact has been corrected.
Returning to FIG. 15 , the image preprocessing Stage 110 also may process the captured image data by cropping the image to the area occupied by channels 15 themselves (block 160). As described, each test bed may include a pair of wells interconnected by a plurality of channels. For much of the migration analysis, it is Sufficient to measure cellular movement or activity within channels 15 only. Activity in Second well 14 or the first well 13 need not be considered.
In Such an embodiment, the image preprocessing Stage 110 may crop the image data to remove pixels that lie outside channels 15.
The image preprocessing Stage 110 also may include a thresholding block 170, performing threshold detection upon the image data. The thresholding block 170 may truncate to Zero any Sample having a re-Scaled value that fails to exceed a predetermined threshold. Such thresholding is useful to remove noise from the captured image data. In an embodiment, the thresholding block 170 may be inte grated with the equalization block 140 discussed above. It need not be present as a separate element. In Some embodiments, particularly those where the equalization block 140 Scales pixel values according to wavelength components, the thresholding block 170 may be omitted altogether. An output of the image preprocessing Stage 110 may be input to the object identification stage 120. The object identification stage 120 identifies objects from within the image data, including the microchannels themselves and, optionally, individual cells. According to an embodiment, in a fluorescent system, channels 15 may be identified by In an application where cells are marked with nuclear Staining, identification of individual cells merely requires an image processor to identify and count the number of marked nuclei. The nuclei appear is a number of dots of a predetermined color. In an application using fluorescing cells, identification of individual cells becomes more complicated. Individual cells can be identified rela tively easily; they appear as objects of relatively uniform area in the image data. Identifying a number of cells clustered together becomes more difficult. In this case, the number of cells may be determined from the area or radius of the cluster in the image data. The cluster is likely to appear in the image having Some area or cluster radius. By comparing the cluster's area or radius to the area or radius of an individual cell, the number of cells may be interpo lated. Of course, identification of individual cells may be omitted depending upon the requirements of the migration analysis.
The final Stage in the image processing System is the migration analysis 130 itself. In one embodiment, coordinate data of each cell in the channels 15 may be gathered and recorded. However, Some testing need not be So compli cated. In a first embodiment, it may be Sufficient merely to identify the number of cells present in channel 15. According to an embodiment, the image processing may account for manufacturing defects of individual channels 15. During image processing, manufacturing defects may pre vent cell migrations into a channel 15. In an embodiment, when the system 100 counts a number of cells in the channel 15 (or derives the number from identified cell locations), it may compare the number to an expectation threshold. If the number is below the expectation threshold, the system 100 may exclude the channel 15 from migration analysis. In practice, this expectation threshold may be established as a minimum number of cells that are likely to enter a properly configured cell given the test conditions being analyzed under the migration analysis. If the actual number of cells falls below this threshold, it may lead to a conclusion that channel 15 blocking conditions may be present.
The foregoing operations and processes of the analysis System 100 may be performed by general purpose proceSS ing apparatus, Such as computers, WorkStations or Servers, executing Software. Alternatively, Some of the operations or processes may be provided in a digital Signal processor or application specific integrated circuit (colloquially, an "ASIC). Additionally, these operations and processes, par ticularly those associated with image preprocessing, may be distributed in processors of a digital microScope System. Such variations are fully within the scope of the present invention.
The present invention also contemplates the use of the aforementioned embodiments of device 10 to assay various elements of chemotaxis, haptotaxis and chemoinvasion. In general, the present invention provides for a first assay comprising high throughput Screening of test agents to determine whether they influence chemotaxis, haptotaxis, and chemoinvasion. Test agents generally comprise either Soluble test Substances or immobilized test biomolecules and are generally placed in first well region 13a of chamber 12 of device 10. After determining which test agents influence chemotaxis, by acting as chemoattractants and promoting or initiating chemotaxis, by acting as chemorepellants and repelling chemotaxis, or by acting as inhibitors and halting or inhibiting chemotaxis, then a Second assay can be per formed Screening test compounds. The test compounds generally comprise therapeutics or chemotaxis/haptotaxis inhibitors and are generally introduced in Second well region 14a, which contains a biological Sample of cells. The test compounds are Screened to determine if and how they influence the cells chemotaxis or haptotaxis in response to the test agents.
In particular, a chemotaxis/haptotaxis and/or chemoinva Sion assay according to an embodiment of the present invention involves a device 10 including a housing com prising a top member 11 mounted to a Support member 16. The top member and the Support member are configured Such that they together define a discrete assay chamber 12. The discrete assay chamber 12 includes a first well region 13a connected by a channel 15 to a second well region 14a. The first well region 13a includes at least one first well 13, each of the at least one first well 13 being adapted to receive a test agent therein. The Second well region 14a includes at least one second well 14 horizontally offset with respect to the first well region 13a in a test orientation of the device, each of the at least one Second well 14 being adapted to receive a cell Sample therein. Channel 15 includes at least one channel connecting the first well region 13a and the Second well region 14a to one another. Non-limiting examples of chemorepellants include irri tants Such as benzalkonium chloride, propylene glycol, methanol, acetone, Sodium dodecyl Sulfate, hydrogen peroxide, 1-butanol, ethanol, and dimethylsulfoxide, and to Xin S. Such as cyanide, carbonylcyanide chlorophenylhydra Zone, endotoxins and bacterial lipopolysaccharides, viruses, pathogens, and pyrogens.
Nonlimiting examples of immobilized biomolecules include chemoattractants, chemorepellants, and chemotactic In order to perform a test, Such as a chemotaxis and/or chemoinvasion assay utilizing a Soluble test Substance, the test device 10 is first fabricated. A preferred embodiment of the method of making the device according to the present invention will now be described. A master that is the negative of top-plate 11 is fabricated by Standard photolitho graphic procedures. A predetermined material is spin coated or injection molded onto the master. The predetermined material is then cured, peeled off the master to comprise top member 11 and placed onto support member 16.
Where the test device 10 is a chemotaxis, haptotaxis and/or chemoinvasion device, a rigid frame with the Stan dard microtiter footprint is preferably placed around the outer perimeter of top member 11. In one embodiment, a gel matrix is poured into well region 13a and allowed to flow into channel region15.a. After the gel matrix sets, excess gel is removed from well regions 13a and 14a. In another embodiment, no gel matrix is added to channel region 15a. Subsequently, a biological Sample of cells is placed in well region 14a and a test Substance is placed in well region 13a. The concentration of biomolecules increases or decreases along the longitudinal axis of the device from the upper Surface of Support member 16 constituting the bottom Sur face of well region 13a towards the upper surface U of support member 16 constituting the bottom surface of well region 14a thus forming a Surface gradient. After the test biomolecules are immobilized on support member 16, the top member is placed onto Support member 16 and a rigid frame with the Standard microtiter footprint is placed around the outer perimeter of top member 11 and cells are added to well region 14a. In an alternative embodiment, after the test biomolecules are immobilized on Support member 16 and the top member is placed over Support member 16, a gel matrix is added to channel region 15a. Cells are Subse quently added to well region 14a. The biological Sample of cells potentially respond to the concentration gradient of immobilized biomolecules and migrates towards the higher concentrations of the test biomolecules, away from the higher concentrations of the test biomolecules, or exhibit inhibited migration in response to the higher concentrations of the test biomolecules. The Surface gradient can increase linearly or as a Squared, cubed, or logarithmic function or in any Surface profile that can be approximated in StepS up or down.
The test biomolecules can be attached to and form Surface gradients on the upper Surface U of Support member 16 by various specific or non-specific approaches known in the art as described in K. Efimenko and J. Genzer, "How to Prepare Tunable Planar Molecular Chemical Gradient," 13 Applied The present invention also contemplates an assay using both a soluble and surface gradient to determine whether the Soluble test Substance or the immobilized test biomolecules more heavily influence chemotaxis and chemoinvasion. In this embodiment, an assay is performed by forming a Surface gradient as described above, an assay is performed by forming a Solution gradient as described above, an assay is performed by forming both types of gradients and the results of all three assays are compared. With respect to the com bined gradient assay, test biomolecules are immobilized on the upper Surface U of Support member 16 constituting the bottom Surface of well region 13a and on the upper Surface of Support member 16 underlying channel region 15a and the concentration of biomolecules decreases along the lon gitudinal axis of chamber 12 from well region 13a to well region 14a, in any one of the embodiments of the test device 22 of the present invention, Such as the embodiments shown in FIGS. 1A-14. Additionally, a soluble test Substance is added to well region 13a. Such an embodiment creates Surface and Soluble chemotactic concentration gradients that decrease in the same direction. If the combined concentration gradients have a Synergistic effect on chemotaxis and/or chemoinvasion, then both gradients should be used in Screening both the cell receptor binding the chemotactic ligands of the Soluble chemotactic Substance and the cell receptor binding the immobilized biomolecules. Both types of receptors are identified as important and therapeutic agents that target both these receptorS or a combination of therapeutic agents, one targeting one receptor and another targeting the other receptor can be Screened. If the combined concentration gradients do not have a Synergistic effect, then the individual gradient that more Strongly promotes chemo taxis and/or chemoinvasion can be identified and the cell receptor that binds to the chemotactic ligands of the test agent forming the gradient can be targeted.
Identifying optimal chemotactic ligand and receptor pairs is important in understanding the biological pathways impli cated in chemotaxis and/or chemoinvasion and developing therapeutic agents that target these pathways. Accordingly, the present invention generally provides using chemotactic test agents to determine which chemotactic receptors expressed on a cell's Surface most heavily influence chemo taxis and/or chemoinvasion. In one embodiment, the present invention provides for high throughput Screening of a class of chemoattractants known to attract a particular cell type having a receptor on the cell's Surface for each chemoat tractant within this class in order to identify which receptor is more strongly implicated in the chemotaxis and/or chemo invasion process. After identifying this receptor, the present invention contemplates high-throughput Screening of thera peutic agents that potentially block this receptor or bind to this receptor, depending on whether chemotaxis and/or chemoinvasion is desired to be promoted or prevented. In another embodiment, the present invention provides for high throughput Screening of different chemoattractants known to bind to the same receptor on a particular cell type's Surface, in order to determine which chemoattractant ligand/receptor pair more heavily influences chemotaxis and/or chemoinva Sion. After identifying this ligand/receptor pair, the present invention contemplates high throughput Screening of thera peutic agents that target this receptor and either block or activate this receptor depending one whether chemotaxis and/or chemoinvasion is desired to be promoted or pre vented.
The present invention also contemplates high-throughput Screening of a class of chemotactic inhibitors known to inhibit chemotaxis of a particular cell type having various chemotactic receptors on the cells Surface in order identify which receptor is more Strongly implicated in the chemot axis and chemoinvasion process. After identifying this receptor, the present invention provides for high throughput Screening of therapeutic agents that potentially block this receptor as well (if Such action is desired).
In one embodiment of the present invention, an assay is performed to determine whether a test compound inhibits cancer cell invasion. In this embodiment, untreated cancer cells are placed in well region 14a and a test agent is placed in well region 13a of chamber 12 in any one of the embodiments of the test device of the present invention, Such as the embodiments shown in FIGS. 1A-14. Cell chemotaxis and invasion is measured and recorded. After a Suitable test agent is identified (one that chemically attracts the cancer cells) another assay is run in chamber 12. In this Subsequent assay, cancer cells are placed in well region 14a and a test compound, for example, a therapeutic, is also placed in well region 14a. In another embodiment, the test compound is also placed in channel region 15a. If a gel matrix is to be added to channel region 15a, the test compound can be mixed with the gel matrix before the gel is contacted with channel region 15a during fabrication of device 10. A Subsequent Sample of the test agent identified in the first assay is placed in well region 13a and the chemotaxis and invasion of the cells treated with the test compound is compared to the chemotaxis and invasion of the cells not treated with the test compound. The test compounds anti-cancer potential is measured by whether the treated cancer cells have a slower chemotaxis and invasion rate than the untreated cancer cells.
With respect to another exemplary use of the chemotaxis and chemoinvasion device of the present invention, the device can be used to assay cells response to the inflam matory response. A local infection or injury in any tissue of the body attracts leukocytes into the damaged tissue as part of the inflammatory response. The inflammatory response is mediated by a variety of Signaling molecules produced within the damaged tissue site by mast cells, platelets, nerve endings and leukocytes. Some of these mediators act on capillary endothelial cells, causing them to loosen their attachments to their neighboring endothelial cells So that the capillary becomes more permeable. The endothelial cells are also Stimulated to express cell-Surface molecules that rec ognize specific carbohydrates that are present on the Surface of leukocytes in the blood and cause these leukocytes to adhere to the endothelial cells. Other mediators released from the damaged tissue act as chemoattractants, causing the bound leukocytes to migrate between the capillary endot helial cells into the damaged tissue. To Study leukocyte chemotaxis, in one embodiment, channel region 15a is treated to Simulate conditions in a human blood capillary during the inflammatory response. For example, the side walls of channel region 15a are coated with endothelial cells expressing cell Surface molecules Such as Selecting, for example as shown in FIG. 4B. Leukocytes are then added to well region 14a and a known chemoattractant is added to well region 13a in any one of the embodiments of the test device of the present invention, Such as the embodiments shown in FIGS. 1A-14. Other suitable cell types that can be added to well region 14a are neutrophils, monocytes, T and B lymphocytes, macrophages or other cell types involved in response to injury or inflammation. The leukocytes chemo taxis acroSS channel region 15a towards well region 13a is observed. Depending on the type of infection to be studied, different categories of leukocytes can be used. For example, in one embodiment Studying cell chemotaxis in response to a bacterial infection, well region 14a receives neutrophils. In another embodiment Studying cell chemotaxis in response to a viral infection, well region 14a receives T-cells. In another embodiment Simulating the process of angiogenesis, it is known in the art that growth factors applied to the cornea induce the growth of new blood vessels from the rim of highly vascularized tissue Surrounding the cornea towards the Sparsely vascularized center of the cornea. Therefore in another exemplary assay utilizing the chemotaxis and chemoinvasion device, cells from corneal tissue are placed in well region 13a and endothelial cells are placed in well region 14a in any one of the embodiments of the test device of the present invention, Such as the embodiments shown in FIGS. 1A-14. A growth factor is added to well region 13a and chemotaxis of the endothelial cells is observed, mea Sured and recorded. Alternatively, Since angiogenesis is also important in tumor growth (in order to Supply oxygen and nutrients to the tumor mass), instead of adding growth factor to well region 13a, cancer cells from corneal tissue that produce angiogenic factorS Such as vascular endothelial growth factor (VEGF) could be added to well region 13a and normal endothelial cells added to well region 14a. In a different embodiment also related to the study of angiogenesis, mast cells, macrophages, and fat cells that release fibroblast growth factor during tissue repair, inflammation, and tissue growth are placed in well region 13a and endothelial cells are placed in well region 14a. Since during angiogenesis, a capillary Sprout grows into Surrounding connective tissue, to further simulate conditions in Vivo, channel region 15a can be filled with a gel matrix.
There are several variations and embodiments of the aforementioned assays. One embodiment involves the num ber of channels connecting well region 13a and well region 14a of chamber 12 of device 10. In one embodiment, Such as the ones shown in FIGS. 3A-3C, there are multiple channels connecting well region 13a to well region 14a. By using multiple channels, multiple assays can be performed Simultaneously using one biological Sample of cells. In Such an embodiment, all assays are performed under uniform and consistent conditions and therefore provide Statistically more accurate results. For example, each assay begins with exactly the same number of potentially migratory cells and exactly the same concentration of test agent. Once a con centration gradient forms, each assay is exposed to the gradient for the Same period of time. These multiple chan nels also provide redundancy in case of failure in the assay.
Another embodiment of the cell invasion and chemotaxis assay of the present invention involves the placement of cells in well region 14a of chamber 12 in any one of the embodiments of the test device of the present invention, Such as the embodiments shown in FIGS. 1A-14. The cells may be patterned in a specific array on the upper Surface U of Support member 16 constituting the bottom Surface of well region 14a or may simply be deposited in no specific pattern or arrangement in well region 14a. If the cells are patterned in a specific array on the upper Surface of Support member 16 constituting the bottom surface of well region 14a, then preferably, during the fabrication of device 10, the upper Surface of Support member 16 constituting the bottom Surface of well region 14a is first patterned with cells and then top member 11 is placed over support member 16. It is desirable to monitor cellular movement from a predeter mined "starting position to accurately measure the distance and time periods the cells travel. AS Such, in one embodiment, the cells are immobilized or patterned upon the Support member underlying the first well in Such a manner that the cells viability is maintained and their position is definable So that chemotaxis and invasion may be observed. There are Several techniques known in the art to immobilize and pattern the cells into discreet arrays onto the Support member. A preferred technique is described in copending application Ser. No. 60/330, 456 . In one embodiment, a cell position patterning member is used to pattern the cells into definable areas onto the upper Surface U of Support member 16 constituting the bottom surface of well region 14a of top member 11. If, for example, top member 11 is fabricated in the footprint of a standard 96-well microtiter plate such that wells 13 and 14 correspond to the size and shape of the macroWells of the microtiter plate (not shown), then the cell position pattern member has outlined areas which corre spond to the size and shape of wells 13 and 14 and therefore correspond to the size and shape of the macroWells of the microtiter plate. Each outlined area has micro through holes through which the cells will be patterned. In order to pattern the cells, the cell position patterning member iscontacted with Support member 16 and the outlined areas of the cell position patterning member are aligned with portion of upper Surface U of Support member 16 that constitutes the bottom surface of well region 14a, and will ultimately correspond to well region 14a once top member 11 is contacted with support member 16. Cells are then deposited over the cell position patterning member and filter through the micro through holes of the patterning member onto the Support member underlying the areas corresponding to through-holes corresponding to Second well regions 14a of chambers 12. Top member 11 is then placed over support member 16 Such that through-holes 14a are placed over the area of Support member 16 in which the cells are patterned. These patterning Steps result in discrete arrays of cells in well region 14a.
Preferably, the cell position patterning member comprises an elastomeric material such as PDMS. Using PDMS for the patterning member provides a Substantially fluid-tight Seal between the patterning member and the Support member. This substantially fluid-tight seal is preferable between these two components because cells placed in the Wells are leSS likely to infiltrate adjoining wells if Such a Seal exists between the patterning member and the Support member. The arrangement of the micro through holes of the pattern ing member may be rectangular, hexagonal, or another array resulting in the cells being patterned in these respective shapes. The width of each micro-through hole may be varied according to cell types and desired number of cells to be patterned. For example, if the width of both cell and micro through hole is 10 microns, only one cell will deposit through each micro through hole. Thus, in this example, if the width of micro through hole is 100 microns up to approximately 100 cells may be deposited.
The present invention also contemplates the patterning of more than one cell type on the upper Surface of Support member 16 constituting the bottom surface of well region 14a in any one of the embodiments of the test device of the present invention, such as the embodiments shown in FIGS. 1A-14. Since cells of one type in vivo rarely exist in isolation and are instead in contact and communication with other cell types, it is desirable to have a System in which cells can be assayed in an environment more like that of the body. For example, Since cancer cells are never found in isolation, but rather Surrounded by normal cells, an assay designed to test the effect of a drug on cancer cells would be more accurate if the cancer cells in the assay were Sur rounded by normal cells. In testing an anti-cancer drug, cancer cells may be patterned on the upper Surface of support member 16 constituting the bottom surface of well region 14a in any given one of the embodiments of the test device of the present invention, Such as the embodiments of FIGS. 1A-14, and then through a separate patterning procedure, the cancer cells may be Surrounded by Stromal cells. To pattern two different cell types on the upper Surface of Support member 16 constituting the bottom Surface of well region 14a, a micro cell position patterning member, as described above, is contacted with support member 16 and the outlined areas of the cell position patterning member are aligned with the portion of upper Surface U of Support member 16 that constitutes the bottom surface of well region 14a, and will ultimately correspond to well region 14a once top member 11 is contacted with Support member 16. Cells of a first type may then be deposited over the cell position patterning member and filter through the micro through holes of the patterning member onto the portion of the upper Several methods are known in the art to tag the cells in order to observe and measure the aforementioned param eters. In one embodiment, an unpurified Sample containing a cell type of interest is incubated with a staining agent that is differentially absorbed by the various cell types. The cells are then placed in well region 14a of chamber 12 in any given one of the embodiments of the test device of the present invention, such as the embodiments of FIGS.
1A-14. Individual, stained cells are then detected based upon color or intensity contrast, using any Suitable microS copy technique(s), and Such cells are assigned positional coordinates. In another embodiment, an unpurified cell Sample is incubated with one or more detectable reporters, each reporter capable of Selectively binding to a specific cell type of interest and imparting a characteristic fluorescence to all labeled cells. The Sample is then placed in well region 14a of chamber 12 in any given one of the embodiments of the test device of the present invention, Such as the embodi ments of FIGS. 1A-14. The sample is then irradiated with the appropriate wavelength light and fluorescing cells are 27 detected and assigned positional coordinates. One skilled in the art will recognize that a variety of methods for discrimi nating Selected cells from other components in an unpurified Sample are available. For example, these methods can include dyes, radioisotopes, fluorescers, chemiluminescers, beads, enzymes, and antibodies. Specific labeling of cell types can be accomplished, for example, utilizing fluorescently-labeled antibodies. The process of labeling cells is well known in the art as is the variety of fluorescent dyes that may be used for labeling particular cell types.
Cells of a chosen type may be also differentiated in a mixed-cell population, for example, using a detectable reporter or a Selected combination of detectable reporters that selectively and/or preferentially bind to such cells. Labeling may be accomplished, for example, using mono clonal antibodies that bind selectively to expressed CDs, antigens, receptors, and the like. Examples of tumor cell antigens include CD13 and CD33 present on myeloid cells; CD10 and CD19 present on B-cells; and CD2, CD5, and CD7 present on T-cells. One of skill in the art will recognize that numerous markers are available that identify various known cell markers. Moreover, additional markers are con tinually being discovered. Any Such markers, whether known now or discovered in the future, that are useful in labeling cells may be exploited in practicing the invention.
Since few, if any markers are absolutely specific to only a single type of cell, it may be desirable to label at least two markers, each with a different label, for each chosen cell type. Detection of multiple labels for each chosen cell type should help to ensure that the chemotaxis and chemoinva Sion analysis is limited only to the cells of interest.
The present invention further provides a test device comprising: Support means, means mounted to the Support means for defining a discrete chamber with the Support means by being placed in fluid-tight, conformal contact with the Support means. The discrete chamber includes a first well region including at least one first well; a Second well region including at least one Second well, the Second well region further being horizontally offset with respect to the first well region in a test orientation of the device; and a channel region including at least one channel connecting the first well region and the Second well region with one another. An example of the Support means comprises the Support mem ber 16 shown in FIGS. 1A, 1B, 12 and 13, while an example of the means mounted to the Support means comprises the top member 11 shown in FIGS. 1A-11, 13 and 14. Other such means would be well known by persons skilled in the art.
From the foregoing, it will be observed that numerous modifications and variations can be effected without depart ing from the true Spirit and Scope of the novel concept of the present invention. For example, different embodiments of a device of the present invention may be combined. Embodi ments of the present invention further contemplate different types of assays, for example, an assay wherein the test agent comprises a buffer Solution instead of a chemotactic agent. In Such an assay, cell migration through channel region 15a in observed in the absence of a chemotactic gradient.
It will be appreciated that the present disclosure is intended to set forth the exemplifications of the invention, and the exemplifications Set forth are not intended to limit the invention to the specific embodiments illustrated. The disclosure is intended to cover by the appended claims all Such modifications as fall within the Spirit and Scope of the claims. A Silicon wafer (6 inches) is spin coated with photoresist (SU8-50) at 2000 rpm for 45 seconds. After baking the wafer on a hot plate at 115 C. for 10 minutes, the wafer is allowed to cool to room temperature. A mask aligner (EVG620) is used to expose the photoresist film through a photomask. Exposure of 45 seconds is followed by another hard bake at 115 C. for 10 minutes. The silicon wafer is allowed to cool to room temperature for over 30 minutes. The uncrosslinked photoresist is removed using propylene glycol methyl ether acetate (PGMEA). The wafer is dried under a stream of nitrogen, and the patterned photoresist is ready for Subse quent processing.
In one embodiment, the patterned photoresist is spin coated with another layer of SU8-100 at 1500 rpm for 45 Seconds. A mask aligner is used to Selectively expose macrofeatures (i.e. wells) of the top member but not expose channel regions connecting the Wells and other areas of the top member. After post exposure processing and photoresist removal, the master contains multiple layered features. This
Step may be repeated to introduce macro-features on the master, which have the height of approximately 3 mm.
When a PDMS prepolymer is cast against the master, it faithfully replicates the features in the master. When casting, PDMS is added in an amount slightly lower than the height of the macrofeatures. After curing the PDMS for four hours at 65 degrees C., the PDMS is peeled off the silicon master and thoroughly cleaned with Soap and water and rinsed with 100% ethanol. A glass Support member is also cleaned and rinsed with ethanol. The PDMS membrane and glass support member are plasma Oxidized for 1 minute with the Sides that would be bonded together facing upward. The PDMS mem brane is then placed onto the glass Support member and preSSure is applied to remove any air bubbles that may have formed between the PDMS membrane and the glass support member. The assembled device is then cooled to 4 C.
Within 15 minutes of the plasma oxidation of the PDMS membrane and the glass Support member, 20 microliters (ul) of Matrigel (any other hydrogel may be used) is poured into the first well and allowed to flow into the capillaries. The device is placed at room temperature for 15 minutes to Set the Matrigel. Excess gel is then removed from the wells of the top member using a vacuum and a Pasteur pipette.
Example 2 Cell Chemoinvasion Assay Placement of Cells and Test Agent in Chamber
The first and second wells of a chamber of a top member are filled with phosphate buffered saline solution, PBS. The bottom of the second well may be treated with fibronectin (1 mg/ml) or other extracellular matrix protein for 30 minutes, Cells are left to attach and spread in the Second well overnight in a 37 C. incubator. At the start of the experiment, the cell medium is exchanged for fresh Serum free medium. 10 ug of bFGF (basic fibroblast growth factor) per ml of medium is added to the first well of each chamber. Cells are left to attach and Spread in the Second Wells overnight in a 37 C. incubator. At the start of the experiment, the cell medium is exchanged for fresh Serum free medium or 1% serum. 1 tug of bFGF (basic fibroblast growth factor) per ml of medium is added to the first wells of the chamber. A solution gradient is allowed to form for Two wells are filled with 50 ul of PBS, and hydrostatic preSSure is allowed to equalize. 5 ul of anti-hisX6 antibody are added to the first well and 5 ul of buffer are added to the Second well to equalize hydrostatic pressure. By diffusion, the antibody concentration forms a gradient from the first well to the Second well. After 2 hours at room temperature, the two wells are washed off by adding 50 ul of buffer to the second well and removing 50 ul from the first well. By physisorption, the Solution gradient is transferred onto a Surface thereby forming a Surface gradient. A Solution of IL-8 (recombinant human IL-8 with a HISx6 fusion tag, R+D systems, catalog No. 968-IL) at concentration of 25 tug/ml is added to the channel regions. The Solution is allowed to incubate for 30 minutes at room temperature.
Excess IL-8 chemokine is washed off and the Surface is decorated with bound IL-8. Neutrophils(freshly isolated from a healthy donor) are added to the second well. Typi cally 20,000-100,000 cells are added in volume ranging from 10-550 ul. Neutrophils are allowed to adhere to the Support member and allowed to migrate towards the higher concentration of IL-8. Inhibition of migration is achieved by adding polyclonal antibody against IL-8.
What is claimed is:
1. A method of monitoring haptotaxis comprising: providing a device for monitoring haptotaxis having a housing defining a chamber, the chamber including: a first well region including at least one first well, the first well region configured to receive immobilized test biomolecules therein and further including test biomolecules immobilized therein;
a Second well region including at least one Second well, the Second well region configured to receive a Sample comprising cells therein and further being horizontally offset with respect to the first well region in a test orientation of the device; and a channel region with test biomolecules immobilized therein and including at least one channel connecting the first well region and the Second well region with one another.
forming a Surface concentration gradient along a longi tudinal axis of the chamber by decreasing the concen tration of test biomolecules from the at least one first well to the at least one Second well; placing a first Sample comprising cells in the at least one Second well; and monitoring haptotaxis of the cells. 2. The method of claim 1, wherein the chamber comprises a plurality of chambers.
3. The method of claim 2, wherein each of the first well region and the Second well region of the plurality of cham bers are disposed relative to one another to match a pitch of a Standard microtiter plate.
4. The method of claim 2, wherein the plurality of chambers is disposed relative to one another to match a pitch of a Standard microtiter plate.
5. The method of claim 1, wherein the at least one channel comprises a plurality of channels.
6. The method of claim 1, wherein the housing comprises a Support member and a top member, the top member being in reversible, fluid tight conformal contact with the Support member, the top member and the Support member config ured Such that they together define the chamber. 10. The method of claim 1, wherein the test biomolecules are chemokines, cytokines, or Small molecules.
11. The method of claim 1, further comprising adding a test compound to the at least one Second well.
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12. The method of claim 11, wherein the test compound is a therapeutic agent, a chemotactic inhibitor, a chemoattractant, or a chemorepellant.
13. The method of claim 1, wherein the test biomolecules are immobilized in the first well region and the channel region through the use of Self-assembled monolayers.
14. The method of claim 1, wherein placing the first Sample comprising cells in the at least Second well com prises patterning the cells in discrete arrayS.
15. The method of claim 1, further comprising placing a Second Sample comprising cells in the at least one Second well.
